Background {#S1}
==========

Cancer is a complex disease arising from the gradual accumulation of genetic changes resulting in the reprogramming of key cellular processes well described in "The Hallmarks of Cancer" written by Hanahan and Weinberg ([@B1]). Structural and functional alterations in driver genes and entire pathways to fulfill the nutritional requirements are responsible for this reprogramming, and although their mechanisms are not fully known, various drugs have been developed to target actionable mutations ([@B2], [@B3]).

One attractive therapeutic strategy is the inhibition of the mammalian target of rapamycin (mTOR), as well as various downstream and upstream signaling molecules ([@B4]). The mTOR pathway has evolved as nutrient sensing to promote cell proliferation under adequate nutritional and environmental conditions ([@B5]). The activation of mTOR depends on the formation of two complexes called mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) that are activated in distinct ways. mTORC1 controls the protein synthesis and cell survival through the phosphorylation of its substrates, 4EBP1, p70S6K and factor 4G. mTORC1 is inactivated by rapamycin but is activated by growth factors, nutrients, energy and stress signals, and essential signaling pathways (PI3K, MAPK, and AMPK). In contrast to mTORC1, mTORC2 is not inactivated by rapamycin and generally, it is not affected by nutrients and energy signals. mTORC2 regulates cytoskeleton organization and promotes cell survival through the phosphorylation of protein kinase B (Akt) and protein kinase C ([@B6]--[@B8]). The key role of mTOR in these processes explains its association in pathologies such as cancer ([@B9], [@B10]).

Several works and recent cancer genomic projects described high rates of mutations in genes involved in the mTOR pathway, including *PI3K, PTEN, AKT*, and *S6K1, 4EBP1*, and *EIF4E*. Based in this data, mTOR inhibitors (rapamycin and its analogs) have become attractive therapeutic agents tested in several clinical trials, as single agents or in combination with other types of systemic treatment ([@B9]). Unfortunately, some inhibitors of mTOR have shown lack of efficacy, including the rapamycin ([@B11]).

The DNA damage inducible transcript 4 (*DDIT4*) is induced by cellular stress conditions and regulates the mTOR activity ([@B12]), and also its abnormal expression has been linked to multiple diseases, including malignant tumors ([@B13]--[@B18]).

*DDIT4* Gene {#S2}
============

This gene was simultaneously discovered and cloned in 2002 by two independent research groups. Shoshani et al. using a microarray hybridization technique to investigate the hypoxia-dependent gene expression in rat glioma C6 cells reported a gene highly upregulated in response to hypoxia-inducible factor 1 (HIF-1) and regulating the generation of cellular reactive oxygen species (ROS). This gene was designated *RTP801* ([@B19]). Concurrently, Ellisen et al. identified a new p53 target induced by DNA damage and regulated by p63 during embryogenesis and epidermal differentiation. In this study, this gene was alternatively designated *REDD1* (regulated in development and DNA damage response 1), which was also involved in the generation of ROS ([@B20]).

Contemporarily with these works, Wang et al. analyzed which genes are potentially involved in regulating glucocorticoid-induced apoptosis in lymphoid cells. Through an oligonucleotide microarray analysis, they discovered a novel dexamethasone-induced gene designated *Dig2* whose expression is significantly induced in cell lines of murine T-cell lymphoma and in normal mouse thymocytes ([@B21]). The official name given by the HUGO Gene Nomenclature Committee was *DDIT4*.

*DDIT4* is located on chromosome 10 (10q22.1) and has a length of 2.1 kb, containing three exons and two introns ([@B19], [@B20]). *DDIT4* has three splice variants (one it is the protein coding with 232 amino acids and the others are retained introns), 95 orthologs, one paralog (*DDIT4L*, DNA damage inducible transcript 4 like) and is associated with one phenotype ([@B22]). Because of this, it is presumed that it was present in the common ancestor of animals ([@B23]).

*DDIT4* is ubiquitously expressed at low levels in most adult tissues (Figure [1](#F1){ref-type="fig"}) ([@B19]). The *DDIT4* expression is induced by multiple cellular stresses, such as hypoxia ([@B19], [@B24]), ionizing radiation (IR) ([@B20]), methyl methane sulfonate (MMS) ([@B25]), heat shock ([@B21]), and energy depletion ([@B12]). Moreover, it is also upregulated by other chemical molecules, such as glucocorticoids ([@B21], [@B26], [@B27]), dopaminergic neurotoxins ([@B28]), endoplasmic reticulum stress inducers ([@B21], [@B29]), DNA damage agent etoposide ([@B21]), and arsenite ([@B30]). Conversely, *DDIT4* expression decreases by testosterone, acute resistance exercise, refeeding/nutrient consumption, and suppressed mTORC1 ([@B31]).

![DNA damage inducible transcript 4 (*DDIT4*) gene expression. *DDIT4* is ubiquitously expressed in multiple human tissues ([@B32]).](fonc-08-00106-g001){#F1}

DDIT4 Protein {#S3}
=============

With an estimated half-life of approximately 5 min ([@B33], [@B34]), DDIT4 is a highly conserved protein composed of 232 amino acids, rich in leucine (17%) and contains conserved 9- or 10-serine stretches at its N-terminal end. Its molecular weight is 25 kDa, but it migrates around 35 kDa on Western blot because of its multiple lysine residues at the carboxyl terminus ([@B19], [@B20]). In addition, DDIT4 is mainly present in the cytoplasm and the nucleus ([@B20], [@B30]), but it has also been observed in membranes ([@B35]).

The crystal structure of DDIT4 (PDB ID\# 3LQ9) shows that this protein has two chains (A and B), where each chain has antiparallel α-helices followed by four β-strands with two highly conserved residues (residues 138--141 and 218--225) that might be essential for the activity of the protein (Figure [2](#F2){ref-type="fig"}). Amino acids in position 85--193 and 207--225 correspond to linear segments required for its function, separated by a dispensable region. The extreme N-terminus has 84 amino acids residues poorly preserved among species and dispensable for the function of the protein. By contrast, the C-terminal region is highly conserved and essential for the correct function of DDIT4. Internal deletions and NAAIRS (the sequence Asn--Ala--Ala--Ile--Arg--Ser) substitutions are poorly tolerated because this causes the protein to change to an unphysiological conformation ([@B36]).

![Crystal structure of the human protein DNA damage inducible transcript 4 (PDB ID\# 3LQ9). Both of their chains have antiparallel α-helices followed by four β-strands.](fonc-08-00106-g002){#F2}

Regulation of DDIT4 {#S4}
===================

*DDIT4* expression is upregulated by several transcription factors in response to different stressors ([@B37]). For example, under hypoxic conditions, HIF-1 increases the transcription of *DDIT4* by binding to a hypoxia response element of the *DDIT4* promoter causing downregulation of mTOR ([@B19], [@B24]). Telomere destabilization by DNA-damaging agents also increases *DDIT4* expression through multiple pathways. In mouse embryo fibroblasts (MEFs), IR induces *DDIT4* expression through p53 pathway in a dependent manner ([@B20]). Similarly, in HaCaT human keratinocytes, MMS induces *DDIT4* expression through Elk-1 pathway and CCAAT/enhancer-binding protein (C/EBP) but in a p53-independent manner ([@B25]). Another transcription factor is the nuclear factor of activated T-cells 3, whose overexpression increases c-Myc (mTOR downstream target) and MUC2 expression (a marker of goblet cell differentiation) through the induction of *DDIT4* expression; important process to the regulation of intestinal cell differentiation ([@B38]).

MicroRNAs, small and highly conserved non-coding RNA molecules, are also involved in tumorigenesis by regulating (at posttranscriptional level) specific oncogenes and tumor suppressor genes ([@B39]--[@B41]), such as *DDIT4*. miR-221 overexpression contributes to liver tumorigenesis through the cyclin-dependent kinase inhibitor p27 (Kip1-CDKN1B) and/or *DDIT4* downregulation ([@B42]). miR-495, directly upregulated by the transcription factors E12/E47 in breast cancer stem cells promotes oncogenesis and hypoxia resistance *via* downregulation of E-cadherin and *DDIT4* ([@B43]). miR-30c plays a key role in radiation-induced cell damage because, maybe in part, it downregulates *DDIT4* expression in human hematopoietic and osteoblast cells after gamma-irradiation ([@B44]). miR-630 has a bimodal role in the regulation of apoptosis in response to DNA damage; it promotes apoptosis by downregulation of cell cycle kinase 7 kinase, and on the other hand, it reduces apoptosis by downregulating apoptotic activators, such as DDIT4, PARP3, EP300, and p53 ([@B45]).

At posttranslational level, DDIT4 is quickly degraded by the ubiquitin-proteasome system to allow cells to restore mTOR signaling once the stress conditions have been mitigated. One of the models reported by Katiyar et al. consists in the phosphorylation of DDIT4 by GSK3-β, which causes the recruitment of the Cullin 4A (CUL4A)--DNA damage-binding protein 1--regulator of cullins 1--β-transducin repeat containing protein (β-TRCP) E3 ligase complex, that results in DDIT4 ubiquitination and degradation by the proteasome ([@B34]). Amplification and overexpression of *CUL4A* have been observed in primary breast cancers ([@B46]) and others types of cancers such as hepatocellular carcinomas ([@B47]), so it could be considered as a potential predictive and prognostic indicator of some cancers. In addition, increased β-TRCP mRNA and protein expression have also been found in colorectal and pancreatic cancers ([@B48], [@B49]). By contrast, Tan and Hagen reported that there is an alternative E3 ligase (currently unknown) responsible for both basal DDIT4 ubiquitination and ubiquitination that is induced upon mTORC1 inhibition ([@B50]). These processes sustain that the dysregulation of DDIT4 degradation could be a common event that elevates mTOR signaling during tumor development.

*DDIT4* Inhibits the Activity of mTOR *VIA* Tuberous Sclerosis Complex (TSC1/TSC2 Complex) {#S5}
==========================================================================================

All the stressors mentioned above, *via* different transcription factors, elevate the *DDIT4* expression to fulfill its main function, inhibit mTORC1 to regulate key cellular processes, such as cell growing, proliferation, and survival ([@B12], [@B24]). This inhibitory effect was initially identified in *Drosophila*, where expression of *Scylla* (homologous protein of DDIT4 in *Drosophila*) suppress the phosphorylation of S6K (a known substrate of TOR) ([@B51]); a similar process that was later confirmed in mammalian cells ([@B52]). In addition, TSC1/TSC2 complex does not interact directly with mTORC1, but it functions as a GTPase, inactivating to Rheb, converting Rheb-GTP into Rheb-GDP, unable to activate the mTORC1 complex ([@B53]).

Gordon et al. proposed two models of the effect of DDIT4 in the mTOR pathway. One model proposes that DDIT4 competes with TSC2 to bind with the 14-3-3 proteins. DDIT4 expression increases causing the dissociation of the 14-3-3 proteins with TSC2, so TSC2 is released to form a functional TSC1/TSC2 complex that inhibits mTORC1 activity ([@B31], [@B35]). However, functional and structural analysis has concluded that it is unlikely that DDIT4 interacts directly with 14-3-3 proteins, discarding this model ([@B36]). The other model proposes that phosphatase-2A recruit to Akt causing the reduction of Akt phosphorylation, which in turn causes the reduction of phosphorylation of TSC2 and its induction. The TSC1/TSC2 complex is formed and subsequently represses mTORC1 activity. By contrast, TSC1/TSC2 complex positively regulates mTORC2 through association with rapamycin-insensitive companion of mTOR ([@B31]) (Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}).

![Analysis in STRING-DB v.10.5 describes that DNA damage inducible transcript 4 (DDIT4) is involved in the regulation of at least three clusters of proteins, (i) mammalian target of rapamycin (mTOR) pathway proteins (in red), (ii) p53 pathway (in sky blue), and (iii) 14-3-3 proteins (in green).](fonc-08-00106-g003){#F3}

![DNA damage inducible transcript 4 (DDIT4) controls mammalian target of rapamycin (mTOR) by the activation of the TSC1/TSC2 complex. When the TSC1/TSC2 complex inactivates Rheb, it is unable to activate mTOR complex 1.](fonc-08-00106-g004){#F4}

DDIT4 and Autophagy {#S6}
===================

Autophagy is a catabolic mechanism of cellular adaptation to nutrients deprivation in which cellular components are degraded to its elementary molecules and recycled to promote the cell survival ([@B54]). In addition, autophagy participates in the removal of old or damaged cellular organelles and has been associated with the survival of cancer cells ([@B55]). Autophagy is the opposite response to cell growth and proliferation induced by mTOR activity. Under favorable nutritional conditions, the complex mTORC1 represses autophagy by phosphorylation of the ULK protein complex turning it in an open structural conformation (inactive form). DDIT4-mediated mTOR repression produces the lack of phosphorylation of the ULK complex, turning the complex in a closed structural conformation (active form) activating the mechanism of autophagy and triggering the formation of the autophagosome ([@B56]).

Role of *DDIT4* in Cancer {#S7}
=========================

Dysfunction of *DDIT4* has been associated with multiple diseases, such as neurodegenerative disorders ([@B28], [@B57]), ischemic proliferative retinopathy ([@B58]), preeclampsia ([@B59]), diabetes, and other degenerative pathologies, such as cancer ([@B10]). Results of *in vitro* studies suggest that *DDIT4* could have a context-dependent contrasting role in cancer as oncogene or tumor suppressor ([@B19], [@B60]).

Hyperactivation of the PI3K-Akt-mTOR signaling is a common alteration in cancer. This pathway regulates cellular processes involved in cell growth, proliferation, motility, survival, and apoptosis ([@B61]). In normal cells, PI3K-Akt-mTOR signaling is controlled by PTEN through PI3K dephosphorylation ensuring a transient and controlled activation. On the other hand, PTEN inactivation causes a chronic activation of PI3K and its downstream effectors, such as Akt, promoting the cell cycle progression, survival, and decreased apoptosis ([@B62]).

To know which genes are involved in the growth of cancer cells *via* chronically activated PIK-3 (such as in *PTEN^−/−^* cells), Schwarzer et al. compared *PIK3* expression between cells that have active *PIK-3* versus cells in which it is silenced. They found that *DDIT4* mRNA was significantly downregulated in prostate cancer cells (PC-3) using LY294002 (2-morpholin-4-yl-8-phenylchromen-4-one) or rapamycin, both inhibitors of PI3K, in combination with matrigel-based 3D culture system. By contrast, *DDIT4* was overexpressed under hypoxic conditions in a HIF-1α dependent manner. They also verified their results with other methods, as, for example, inhibiting the function of *DDIT4* employing antisense molecules or interference RNA, which indicates that DDIT4 is a transcriptional downstream target in the PI3K pathway and essential for invasive growth of PC-3 both *in vitro* and *in vivo* ([@B13]).

On the other hand, *DDIT4* has a key role in RAS signaling to transform human ovarian epithelial cells. *DDIT4* is overexpressed in RAS-transformed human ovarian epithelial cells lines T29 and T80 promoting cell proliferation and colony formation. *DDIT4* is overexpressed after activation of *RAS* oncogene, increasing levels of anti-apoptotic proteins and at the same time decreasing expression of pro-apoptotic proteins ([@B60], [@B63]).

Several works have described an involvement of *DDIT4* in the breast cancer biology, while its expression seems to have different patterns among breast cancer subtypes. Koo and Jung characterized the expression of proteins involved in mTOR and hypoxia pathway with staining with immunohistochemistry where immunophenotypes of breast cancer were determined by the evaluation of estrogen and progesterone receptors and HER2 while breast papilloma samples were included as controls ([@B64]).

In this study, Glut-1 and HIF-1α had higher expression in triple-negative breast cancer (TNBC) and HER2 phenotypes than in the luminal A and B phenotypes. These findings could be explained by the greater hypoxia conditions present in TNBC and HER2 tumors. Likewise, Ki-67 expression in TNBC and HER2 was higher than in other phenotypes or papilloma. Interestingly, downregulation of DDIT4 does not lead to a negative feedback to HIF-1 α, so the tumorigenesis mediated by HIF-1α is constant. Moreover, this study demonstrated that HIF-1α expression was associated with reduced disease-free survival (DFS) and reduced overall survival (OS), concordant with previous studies ([@B65]--[@B67]). Concluding that TNBC and HER2 overexpression showed the highest cell proliferation and survival in a hypoxic tumor environment by activation of the mTOR pathway and HIF-1α stabilization *via* DDIT4 downregulation ([@B64]).

*DDIT4* participate in an endogenous feedback circuit with p53. When cells and tissues of *DDIT4*^−/−^ mice are exposed to IR and chemotherapy treatment, the genetic loss of *DDIT4* confers an increase in DNA damage-induced apoptosis both *in vitro* and *in vivo*, which is associated with elevated levels of p53 protein following DNA damage. It was proved that deregulation of p53 is not due to increased p53 stabilization or failed DNA repair but, instead, to increased p53 translation. Consistent with this, it was demonstrated that *DDIT4* loss elevates the mTORC1 activity, which explains the increased p53 translation and damage sensitivity in *DDIT4*^−/−^ cells ([@B68]).

Under stress conditions mTORC1 is also inhibited by the activation of p53 both dependently and independently of Sertrin1/2, suggesting the existence of more than one pathway to inhibit mTORC1 ([@B69]--[@B71]). To test this, Cam et al. exposed MEFs and *in vivo* tumor models to drugs that induce DNA damage to analyze the upstream regulation of mTORC1 signaling. They found that inhibition of mTORC1 signaling to 4EBP1 requires the coordinated activity of both p53 and p63; by contrast, the inhibition of S6K1 and rpS6 phosphorylation is Akt-dependent. Concordant with this, the loss of p53 or p63 prevents the suppression of mTORC1 signaling induced by the DNA damage, supporting that both are necessary for the inhibition of mTORC1. Suggesting that there are multiples mechanisms that suppress p53/p63 responses and at the same time suppress the ability of the cancer cell to control mTORC1 ([@B72]).

In response to DNA damage, DDIT4 phosphorylates downstream Akt through the TSC1/TSC2 complex to inhibit mTORC1 signaling ([@B73], [@B74]). To investigate the clinical significance of this process, Wei et al. analyzed the DDIT4 and p-Akt expression in ovary cancer (primary ovarian cancer and borderline tumors) and normal fallopian tubes. Both DDIT4 and p-Akt expressions were significantly higher in patients with serous ovarian cancer and late FIGO stage; while only DDIT4 expression was significantly higher in ascites formation and only p-Akt expression was significantly histological grade and chemoresistance. Features of patients with improved outcomes in terms of DFS and OS were low DDIT4 staining or absence of p-Akt. In this work, there was no association between *KRAS* mutations and DDIT4 intensity staining, suggesting that *KRAS* is not involved in the activation of DDIT4 ([@B15]).

In contrast to the study performed by Koo and Jung, where they reported that *DDIT4* is downregulated in TNBC and HER2 overexpression types ([@B64]), Pinto et al. found that *DDIT4* is associated with poor prognosis in TNBC resistant to neoadjuvant chemotherapy ([@B17]).

All these data presented previously show that *DDIT4* has a key role in different types of cancer and its aggressiveness. A recent *in silico* analysis of *DDIT4* expression in several cancer types showed that the high expression of this gene was related to a bad outcome in diverse hematologic and solid tumors, such as acute myeloid leukemia, breast cancer, glioblastoma multiforme, melanoma, lung, and colon cancer. Furthermore, it was shown that response to rapamycin and others mTOR inhibitors were not influenced by *DDIT4* expression ([@B18]).

Concluding Remarks and Future Perspectives {#S8}
==========================================

The increasing evidence about the involvement of *DDIT4* in key cellular mechanisms of tumor aggressiveness suggests its driver role in cancer and consequently, its potential not only as prognostic biomarker but also as a therapeutic target. Since mTOR inhibitors have shown disappointing results in the treatment of cancer, where the main issues are the lack of a biomarker to select patients who will benefit from these drugs and the poor knowledge about mechanisms of resistance, a better therapeutic strategy would be *DDIT4* inhibition. In contrast to mTOR expression, the high *DDIT4* expression is related with a poor outcome. We hypothesize DDIT4 targeting could lead to cancer cells to avoid the metabolic suppression needed for cell survival under stress conditions (e.g., treatment with cytotoxic chemotherapy or radiotherapy). Combination of DDIT4 inhibitors with DNA-damaging agents, such as cisplatin, will be interesting, especially in tumors with loss of function of *TP53*, because wild-type p53 repress the expression of DDIT4 in a regulatory loop, potentiating the effects of DDIT4 inhibitors.
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